Cargando…

P611: CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA

Detalles Bibliográficos
Autores principales:	Kusowska, Aleksandra, Krawczyk, Marta, Forcados, Christopher, Marit Inderberg, Else, Wälchli, Sébastien, Winiarska, Magdalena, Bobrowicz, Małgorzata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429305/ http://dx.doi.org/10.1097/01.HS9.0000969348.69513.e8

Ejemplares similares

Determination of CAR T cell metabolism in an optimized protocol
por: Joaquina, Sandy, et al.
Publicado: (2023)

Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
por: Kusowska, Aleksandra, et al.
Publicado: (2022)

In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies
por: Kubacz, Matylda, et al.
Publicado: (2022)

Sympathetic improvement of cancer vaccine efficacy
por: Inderberg, Else Marit, et al.
Publicado: (2020)

Long-term surviving cancer patients as a source of therapeutic TCR
por: Inderberg, Else Marit, et al.
Publicado: (2020)

CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
por: Bobrowicz, Malgorzata, et al.
Publicado: (2020)

Colorectal cysts as a validating tool for CAR therapy
por: Dillard, Pierre, et al.
Publicado: (2020)

How CAR T Cells Breathe
por: Forcados, Christopher, et al.
Publicado: (2022)

Combinatorial CAR design improves target restriction
por: Köksal, Hakan, et al.
Publicado: (2020)

The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era
por: Miazek-Zapala, Nina, et al.
Publicado: (2021)

Efficient chimeric antigen receptor targeting of a central epitope of CD22
por: Casey, Nicholas Paul, et al.
Publicado: (2023)

Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
por: Mensali, Nadia, et al.
Publicado: (2019)

P1376: IDENTIFICATION OF SURFACEOME CHANGES IN CD19 CAR-T THERAPY-RESISTANT LYMPHOMA CELLS
por: Krawczyk, Marta, et al.
Publicado: (2023)

Chimeric antigen receptor preparation from hybridoma to T-cell expression
por: Köksal, Hakan, et al.
Publicado: (2019)

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
por: Inderberg, Else M., et al.
Publicado: (2017)

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
por: Dillard, Pierre, et al.
Publicado: (2021)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

A TCR-based Chimeric Antigen Receptor
por: Walseng, Even, et al.
Publicado: (2017)

Pharmacologic Control of CAR T Cells
por: Caulier, Benjamin, et al.
Publicado: (2021)

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
por: Maggadóttir, Sólrún Melkorka, et al.
Publicado: (2022)

SAT-611 Abdominal Goiter
por: Bedoya, Pablo, et al.
Publicado: (2019)

NK cells specifically TCR-dressed to kill cancer cells
por: Mensali, Nadia, et al.
Publicado: (2019)

Emerging Biomarkers for Immunotherapy in Glioblastoma
por: Mensali, Nadia, et al.
Publicado: (2022)

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
por: Gill, Saar, et al.
Publicado: (2022)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
por: Liu, Jile, et al.
Publicado: (2023)

Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
por: Bobrowicz, Malgorzata, et al.
Publicado: (2019)

The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(6;11)
por: Kundu, Arpita, et al.
Publicado: (2021)

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
por: Inderberg-Suso, Else-Marit, et al.
Publicado: (2012)

Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy
por: Theodossiou, Theodossis A., et al.
Publicado: (2019)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
por: Blanco, Belén, et al.
Publicado: (2022)

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)

Tektronix 611 storage scope display driver
por: Pettersson, T
Publicado: (1976)

MON-611 Biux2x2
por: Kushchayeva, Yevgeniya, et al.
Publicado: (2019)

The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
por: Zhylko, Andriy, et al.
Publicado: (2020)

Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
por: Mancikova, Veronika, et al.
Publicado: (2021)

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
por: Todorovic, Zeljko, et al.
Publicado: (2022)

6,11-Dihydroxynaphthacene-5,12-dione
por: Tomura, Masaaki, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_sj9vrhone87rqgmmubdfiasjr3